Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice

Testicular germ cell tumors are unique among solid cancers. Historically, this disease was deadly if progressed beyond the stage I. The implementation of cisplatin-based chemotherapy regimens has drastically changed the clinical outcome of metastatic testicular cancer. Several biomarkers were established to refine the prognosis by International Germ Cell Collaborative Group in 1997. Among these, the most significant were primary tumor site; metastatic sites, such as non-pulmonary visceral metastases; and the amplitude of serum tumor markers α-fetoprotein, β-chorionic gonadotropin, and lactate dehydrogenase. Since then, oncology has experienced discoveries of various molecular biomarkers to further refine the prognosis and treatment of malignancies. However, the ability to predict the prognosis and treatment response in germ cell tumors did not improve for many years. Clinical trials with novel targeting agents that were conducted in refractory germ cell tumor patients have proven to have negative outcomes. With the recent advances and developments, novel biomarkers emerge in the field of germ cell tumor oncology. This review article aims to summarize the current knowledge in the research of novel prognostic biomarkers in testicular germ cell tumors.

• Publication year

  2018

• Venue

  Frontiers in Oncology

• Publication date

  2018-11-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fonc.2018.00571PMID 30547014PMCID 6280583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial

  2024cited by this paper
• High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion

  2018cited by this paper
• Re: MicroRNA miR-371a-3p-A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid.

  2018cited by this paper
• Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients.

  2018cited by this paper
• c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors

  2018cited by this paper
• Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors

  2018cited by this paper
• Integrated Molecular Characterization of Testicular Germ Cell Tumors

  2018cited by this paper
• Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206

  2018cited by this paper
• Testicular cancer

  2018cited by this paper
• Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy

  2018influential reference
• Liquid Biopsy Using Whole Blood from Testis Tumor and Colon Cancer Patients—A New and Simple Way?

  2018cited by this paper
• Systemic immune-inflammation index in germ-cell tumours

  2018influential reference
• Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

  2017cited by this paper
• High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.

  2017cited by this paper
• Plasma Cytokines Correlated With Disease Characteristics, Progression‐Free Survival, and Overall Survival in Testicular Germ‐Cell Tumor Patients

  2017cited by this paper
• Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.

  2017cited by this paper
• Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors

  2017cited by this paper
• microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients

  2017cited by this paper
• A Suggested Prognostic Reclassification of Intermediate and Poor‐Risk Nonseminomatous Germ Cell Tumors

  2017cited by this paper
• Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas

  2017cited by this paper
• Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.

  2017cited by this paper
• Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors

  2017influential reference
• Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

  2017cited by this paper
• Perspectives on testicular germ cell neoplasms.

  2017cited by this paper
• Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor

  2017cited by this paper
• Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT).

  2016cited by this paper
• Clinical Response of a Patient to Anti–PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors

  2016cited by this paper
• MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid

  2016cited by this paper
• Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine

  2016cited by this paper
• Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients

  2016cited by this paper
• Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.

  2016cited by this paper
• Clinical response to anti-PD1 immunotherapy in a patient with non-seminomatous germ cell tumor and evaluation of the immune landscape in testicular cancer.

  2016cited by this paper
• Expression of microRNAs of C19MC in Different Histological Types of Testicular Germ Cell Tumour.

  2016cited by this paper
• Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors.

  2016cited by this paper
• Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.

  2016cited by this paper
• miR-223-3p regulates cell growth and apoptosis via FBXW7 suggesting an oncogenic role in human testicular germ cell tumors

  2016cited by this paper
• A Pooled Analysis

  2015cited by this paper
• Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours

  2015cited by this paper
• Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.

  2015cited by this paper
• A retrospective analysis of patients with metastatic germ cell tumor (GCT) treated at Indiana University (IU) from 2000 to 2012.

  2015cited by this paper
• Frequent PD-L1 expression in testicular germ cell tumors

  2015cited by this paper
• MicroRNA miR‐371a‐3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker

  2015cited by this paper
• Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

  2014cited by this paper
• A nationwide cohort study of stage I seminoma patients followed on a surveillance program.

  2014cited by this paper
• Targeted serum miRNA (TSmiR) test for diagnosis and follow‐up of (testicular) germ cell cancer patients: A proof of principle

  2013cited by this paper
• Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

  2013cited by this paper
• PARP expression in germ cell tumours

  2013cited by this paper
• Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

  2013cited by this paper
• MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours

  2012cited by this paper
• Promoter methylation of candidate genes associated with familial testicular cancer.

  2012cited by this paper
• Molecular pathology of lung cancer: key to personalized medicine

  2012cited by this paper
• Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors?

  2012cited by this paper
• Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients

  2012cited by this paper
• Epigenetic regulation of Nanog expression by Ezh2 in pluripotent stem cells

  2011cited by this paper
• Methylation of an intronic region regulates miR-199a in testicular tumor malignancy

  2011cited by this paper
• NANOG promoter methylation and expression correlation during normal and malignant human germ cell development

  2011cited by this paper
• Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells

  2010cited by this paper
• Experimental Therapeutic s , Molecular Targets , and Chemical Biology High DNA Methyltransferase 3 B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors

  2009cited by this paper
• Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.

  2009cited by this paper
• Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

  2007cited by this paper
• Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract.

  2007cited by this paper
• OCT4: biological functions and clinical applications as a marker of germ cell neoplasia

  2007cited by this paper
• A Proof of Principle

  2007cited by this paper
• A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

  2007cited by this paper
• Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.

  2005cited by this paper
• Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults.

  2005cited by this paper
• Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.

  2005cited by this paper
• Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors

  2004cited by this paper
• Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.

  2004cited by this paper
• Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry

  2004cited by this paper
• KIT mutations are common in testicular seminomas.

  2004cited by this paper
• Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.

  2003cited by this paper
• Genome-wide analysis of DNA methylation status of CpG islands in embryoid bodies, teratomas, and fetuses.

  2003cited by this paper
• POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.

  2003cited by this paper
• Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours

  2003cited by this paper
• Characteristic promoter hypermethylation signatures in male germ cell tumors

  2002cited by this paper
• Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis

  2002cited by this paper
• Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.

  2001cited by this paper
• Immunopathology of in situ seminoma

  2000cited by this paper
• Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer.

  2000cited by this paper
• Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.

  1999cited by this paper
• International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

  1997cited by this paper
• International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

  1997cited by this paper
• [Phase II study].

  1995cited by this paper
• Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy

  1994cited by this paper
• The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus.

  1990cited by this paper
• The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus

  1988cited by this paper
• Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

  1987cited by this paper

• Genomic landscape of pediatric germ cell tumors reveals oncogenic mutations and copy number alterations.

  2026cites this paper
• Genomic profiling of urological malignancies using tissue-based next generation sequencing.

  2025cites this paper
• Mobilize the Troops! Military Involvement in the History of Testicular Cancer.

  2025cites this paper
• Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship

  2024cites this paper
• Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors

  2023cites this paper
• Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors

  2023cites this paper
• Biomarkers in Testicular Cancer: Classic Tumor Markers and Beyond.

  2023cites this paper
• Breaking the Mold: Epigenetics and Genomics Approaches Addressing Novel Treatments and Chemoresponse in TGCT Patients

  2023cites this paper
• Liquid biopsy in male genital tract: Testis tumor

  2022cites this paper
• Biomarkers of disease recurrence in stage I testicular germ cell tumours

  2022cites this paper
• Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression

  2021cites this paper
• Role of RNA N6-Methyladenosine Modification in Male Infertility and Genital System Tumors

  2021cites this paper
• Testicular Germ Cell Tumors: Classification, Pathologic Features, Imaging Findings, and Management.

  2021cites this paper
• Molecular characteristics of testicular germ cell tumors: pathogenesis and mechanisms of therapy resistance

  2020cites this paper
• Contemporary management of early stage testicular seminoma.

  2020cites this paper
• Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.

  2020cites this paper
• Promising novel therapies for relapsed and refractory testicular germ cell tumors

  2020cites this paper
• Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers

  2020cites this paper
• ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin’s lymphoma and testicular cancer cells

  2020cites this paper
• Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers

  2019cites this paper
• Understanding the crosstalk of molecular factors and signaling pathways reveals novel biomarkers of cisplatin resistance in testicular germ cell tumors.

  2019cites this paper
• Immune mechanisms and possible immune therapy in testicular germ cell tumours

  2019cites this paper
• Glycan Analysis as Biomarkers for Testicular Cancer

  2019cites this paper
• LATE-STAGE PRESENTATION OF TESTICULAR CANCER PATIENTS ATTENDED A SPECIALIZED HOSPITAL: FINDINGS OF A CROSS-SECTIONAL STUDY

  year unknowncites this paper